Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.68
NVS's Cash to Debt is ranked higher than
63% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. NVS: 0.68 )
NVS' s 10-Year Cash to Debt Range
Min: 0.25   Max: 3.39
Current: 0.68

0.25
3.39
Equity to Asset 0.56
NVS's Equity to Asset is ranked higher than
66% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. NVS: 0.56 )
NVS' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.65
Current: 0.56

0.51
0.65
Interest Coverage 15.75
NVS's Interest Coverage is ranked higher than
60% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 176.76 vs. NVS: 15.75 )
NVS' s 10-Year Interest Coverage Range
Min: 13.56   Max: 30.91
Current: 15.75

13.56
30.91
F-Score: 6
Z-Score: 4.23
M-Score: -2.81
WACC vs ROIC
7.88%
12.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 21.35
NVS's Operating margin (%) is ranked higher than
91% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. NVS: 21.35 )
NVS' s 10-Year Operating margin (%) Range
Min: 17.81   Max: 24.34
Current: 21.35

17.81
24.34
Net-margin (%) 18.51
NVS's Net-margin (%) is ranked higher than
92% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.01 vs. NVS: 18.51 )
NVS' s 10-Year Net-margin (%) Range
Min: 15.35   Max: 31.38
Current: 18.51

15.35
31.38
ROE (%) 14.30
NVS's ROE (%) is ranked higher than
88% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. NVS: 14.30 )
NVS' s 10-Year ROE (%) Range
Min: 12.6   Max: 25.67
Current: 14.3

12.6
25.67
ROA (%) 8.13
NVS's ROA (%) is ranked higher than
87% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. NVS: 8.13 )
NVS' s 10-Year ROA (%) Range
Min: 7.21   Max: 16.18
Current: 8.13

7.21
16.18
ROC (Joel Greenblatt) (%) 54.86
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.87 vs. NVS: 54.86 )
NVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 39.04   Max: 73.12
Current: 54.86

39.04
73.12
Revenue Growth (3Y)(%) -2.00
NVS's Revenue Growth (3Y)(%) is ranked higher than
62% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NVS: -2.00 )
NVS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.9   Max: 73.5
Current: -2

-3.9
73.5
EBITDA Growth (3Y)(%) 5.40
NVS's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. NVS: 5.40 )
NVS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7   Max: 82.8
Current: 5.4

-7
82.8
EPS Growth (3Y)(%) 6.00
NVS's EPS Growth (3Y)(%) is ranked higher than
76% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. NVS: 6.00 )
NVS' s 10-Year EPS Growth (3Y)(%) Range
Min: -7.2   Max: 82.2
Current: 6

-7.2
82.2
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NVS Guru Trades in Q1 2014

Steven Cohen 12,821 sh (+50.30%)
Lee Ainslie 351,580 sh (+31.52%)
Sarah Ketterer 327,343 sh (+16.19%)
Bill Frels 4,105 sh (+15.47%)
HOTCHKIS & WILEY 2,302,956 sh (+10.87%)
Irving Kahn 28,068 sh (+2.56%)
Ken Fisher 5,889,287 sh (+1.77%)
John Buckingham 85,174 sh (+0.68%)
Murray Stahl 29,358 sh (+0.20%)
Jean-Marie Eveillard 13,060 sh (unchged)
John Hussman 221,200 sh (unchged)
Pioneer Investments 85,400 sh (unchged)
Dodge & Cox 46,441,169 sh (-0.10%)
Tweedy Browne 291,500 sh (-0.29%)
Mario Gabelli 10,740 sh (-0.92%)
RS Investment Management 76,544 sh (-4.38%)
PRIMECAP Management 24,014,586 sh (-10.13%)
Manning & Napier Advisors, Inc 314,309 sh (-12.67%)
Jim Simons 96,000 sh (-85.44%)
» More
Q2 2014

NVS Guru Trades in Q2 2014

Louis Moore Bacon 180,000 sh (New)
Dodge & Cox 51,102,219 sh (+10.04%)
Manning & Napier Advisors, Inc 332,704 sh (+5.85%)
Ken Fisher 5,969,963 sh (+1.37%)
Pioneer Investments 86,323 sh (+1.08%)
RS Investment Management 76,745 sh (+0.26%)
Murray Stahl 29,425 sh (+0.23%)
Steven Cohen 69,500 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
Bill Frels 4,105 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 23,846,236 sh (-0.70%)
Tweedy Browne 288,825 sh (-0.92%)
John Buckingham 83,941 sh (-1.45%)
Sarah Ketterer 320,852 sh (-1.98%)
John Hussman 214,000 sh (-3.25%)
Mario Gabelli 10,240 sh (-4.66%)
Irving Kahn 26,368 sh (-6.06%)
HOTCHKIS & WILEY 649,519 sh (-71.80%)
Jim Simons 14,000 sh (-85.42%)
» More
Q3 2014

NVS Guru Trades in Q3 2014

Lee Ainslie 272,570 sh (New)
Ruane Cunniff 7,772 sh (New)
Jim Simons 285,900 sh (+1942.14%)
Irving Kahn 30,368 sh (+15.17%)
Bill Frels 4,331 sh (+5.51%)
Sarah Ketterer 334,171 sh (+4.15%)
Manning & Napier Advisors, Inc 344,881 sh (+3.66%)
Ken Fisher 6,015,233 sh (+0.76%)
John Buckingham 84,337 sh (+0.47%)
Murray Stahl 29,425 sh (unchged)
John Hussman 214,000 sh (unchged)
Pioneer Investments 86,502 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 50,905,449 sh (-0.39%)
Mario Gabelli 10,190 sh (-0.49%)
Jean-Marie Eveillard 12,848 sh (-1.62%)
Tweedy Browne 283,983 sh (-1.68%)
PRIMECAP Management 22,239,448 sh (-6.74%)
RS Investment Management 59,008 sh (-23.11%)
Steven Cohen 21,400 sh (-69.21%)
HOTCHKIS & WILEY 9,646 sh (-98.51%)
» More
Q4 2014

NVS Guru Trades in Q4 2014

Jim Simons 860,800 sh (+201.08%)
Lee Ainslie 519,369 sh (+90.55%)
Manning & Napier Advisors, Inc 358,674 sh (+4.00%)
Irving Kahn 30,968 sh (+1.98%)
Sarah Ketterer 336,278 sh (+0.63%)
HOTCHKIS & WILEY 9,665 sh (+0.20%)
Jean-Marie Eveillard 12,848 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Ken Fisher 6,007,365 sh (-0.13%)
Murray Stahl 29,367 sh (-0.20%)
PRIMECAP Management 22,168,678 sh (-0.32%)
Dodge & Cox 50,324,645 sh (-1.14%)
Bill Frels 4,280 sh (-1.18%)
John Buckingham 82,902 sh (-1.70%)
Pioneer Investments 82,942 sh (-4.12%)
Mario Gabelli 9,590 sh (-5.89%)
Tweedy Browne 266,037 sh (-6.32%)
John Hussman 164,000 sh (-23.36%)
RS Investment Management 3,000 sh (-94.92%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.30
NVS's P/E(ttm) is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 52.50 vs. NVS: 25.30 )
NVS' s 10-Year P/E(ttm) Range
Min: 7.87   Max: 26.22
Current: 25.3

7.87
26.22
Forward P/E 18.59
NVS's Forward P/E is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.73 vs. NVS: 18.59 )
N/A
PE(NRI) 22.90
NVS's PE(NRI) is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.50 vs. NVS: 22.90 )
NVS' s 10-Year PE(NRI) Range
Min: 10.63   Max: 24.89
Current: 22.9

10.63
24.89
P/B 3.34
NVS's P/B is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. NVS: 3.34 )
NVS' s 10-Year P/B Range
Min: 1.69   Max: 4.14
Current: 3.34

1.69
4.14
P/S 4.67
NVS's P/S is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.38 vs. NVS: 4.67 )
NVS' s 10-Year P/S Range
Min: 1.89   Max: 4.84
Current: 4.67

1.89
4.84
PFCF 23.93
NVS's PFCF is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1165.60 vs. NVS: 23.93 )
NVS' s 10-Year PFCF Range
Min: 7.03   Max: 26.79
Current: 23.93

7.03
26.79
POCF 18.05
NVS's POCF is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.96 vs. NVS: 18.05 )
NVS' s 10-Year POCF Range
Min: 5.75   Max: 19.28
Current: 18.05

5.75
19.28
EV-to-EBIT 22.77
NVS's EV-to-EBIT is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.80 vs. NVS: 22.77 )
NVS' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 22.9
Current: 22.77

8.9
22.9
Shiller P/E 24.71
NVS's Shiller P/E is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.82 vs. NVS: 24.71 )
NVS' s 10-Year Shiller P/E Range
Min: 9.28   Max: 25.63
Current: 24.71

9.28
25.63
Current Ratio 1.39
NVS's Current Ratio is ranked higher than
58% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. NVS: 1.39 )
NVS' s 10-Year Current Ratio Range
Min: 1.04   Max: 2.83
Current: 1.39

1.04
2.83
Quick Ratio 1.17
NVS's Quick Ratio is ranked higher than
61% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. NVS: 1.17 )
NVS' s 10-Year Quick Ratio Range
Min: 0.78   Max: 2.48
Current: 1.17

0.78
2.48
Days Inventory 139.62
NVS's Days Inventory is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.83 vs. NVS: 139.62 )
NVS' s 10-Year Days Inventory Range
Min: 117.86   Max: 297.21
Current: 139.62

117.86
297.21
Days Sales Outstanding 58.31
NVS's Days Sales Outstanding is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. NVS: 58.31 )
NVS' s 10-Year Days Sales Outstanding Range
Min: 53.85   Max: 79.16
Current: 58.31

53.85
79.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.81
NVS's Dividend Yield is ranked higher than
95% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. NVS: 2.81 )
NVS' s 10-Year Dividend Yield Range
Min: 1.47   Max: 5.11
Current: 2.81

1.47
5.11
Dividend Payout 0.63
NVS's Dividend Payout is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.92 vs. NVS: 0.63 )
NVS' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.67
Current: 0.63

0.22
0.67
Dividend growth (3y) 6.80
NVS's Dividend growth (3y) is ranked higher than
80% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. NVS: 6.80 )
NVS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 18.5
Current: 6.8

0
18.5
Yield on cost (5-Year) 4.08
NVS's Yield on cost (5-Year) is ranked higher than
95% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVS: 4.08 )
NVS' s 10-Year Yield on cost (5-Year) Range
Min: 2.14   Max: 7.44
Current: 4.08

2.14
7.44
Share Buyback Rate -0.20
NVS's Share Buyback Rate is ranked higher than
84% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. NVS: -0.20 )
NVS' s 10-Year Share Buyback Rate Range
Min: 41.9   Max: -2.5
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.42
NVS's Price/Tangible Book is ranked higher than
52% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NVS: 13.42 )
NVS' s 10-Year Price/Tangible Book Range
Min: 0.16   Max: 35.33
Current: 13.42

0.16
35.33
Price/DCF (Projected) 1.51
NVS's Price/DCF (Projected) is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.70 vs. NVS: 1.51 )
NVS' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 1.53
Current: 1.51

0.77
1.53
Price/Median PS Value 1.48
NVS's Price/Median PS Value is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. NVS: 1.48 )
NVS' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.69
Current: 1.48

0.75
1.69
Price/Graham Number 3.63
NVS's Price/Graham Number is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.78 vs. NVS: 3.63 )
NVS' s 10-Year Price/Graham Number Range
Min: 0.07   Max: 4.84
Current: 3.63

0.07
4.84
Earnings Yield (Greenblatt) 4.40
NVS's Earnings Yield (Greenblatt) is ranked higher than
83% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. NVS: 4.40 )
NVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.4   Max: 11.3
Current: 4.4

4.4
11.3
Forward Rate of Return (Yacktman) 1.59
NVS's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.09 vs. NVS: 1.59 )
NVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 81.5
Current: 1.59

1.3
81.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVSEF.USA, NOT.Germany, NOTA.Germany, NVS N.Mexico, NVS.Argentina, NOVNEE.Switzerland,
Novartis AG was incorporated on February 29, 1996 under the laws of Switzerland. On December 20, 1996, our predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments: Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals dividon researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the or their third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of our production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Novartis Goes A Step Forward In Treating Lung Cancer Mar 02 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Pfizer Takes A Giant Leap In Treatment of Cancer Feb 12 2015 
The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 

More From Other Websites
Medics welcome GSK deal to provide meningitis B vaccine Mar 29 2015
GSK agrees UK deal for meningitis shot after Novartis stand-off Mar 29 2015
Farallon Capital Increases Position in Allergan Mar 28 2015
Science, patients driving rare disease drug research surge Mar 25 2015
From Snitch Pill to Xbox Sensors, Novartis Goes Digital Mar 25 2015
Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog Mar 23 2015
Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in... Mar 21 2015
​Judge rejects Amgen bid to stop biosimilar drug Mar 20 2015
New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI... Mar 20 2015
Amgen Loses Bid to Block a Biosimilar Version of its Best-Selling Drug Mar 20 2015
Judge Denies Amgen's Request to Block Novartis's Biosimilar of Neupogen Mar 19 2015
Novartis Wins Judge’s Approval to Sell First-of-Kind Copycat Mar 19 2015
Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog Mar 18 2015
Novartis Division is Charged with Sex Discrimination by Former Employees Mar 18 2015
Alcon targeted in $110M gender discrimination lawsuit Mar 18 2015
Novartis unit hit with $110 million gender discrimination suit Mar 17 2015
Novartis unit hit with $110 mln gender discrimination suit Mar 17 2015
Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for... Mar 17 2015
Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient... Mar 13 2015
XOMA Reports Narrower Y/Y Loss in Q4, Misses on Revs - Analyst Blog Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK